We, therefore, investigated the association between the TP53 mutation and the 21-gene RS in patients with ER+/HER2− BC and evaluated the molecular characteristics of ER+/HER2− BC with the TP53 mutation using The Cancer Genome Atlas (TCGA) database. This evidence concerns the gene TP53 and breast cancer.